BRISTOL BLADDER TRIAL

Cancer type: Muscle-invasive bladder cancer

This trial is looking at the chemotherapy drugs cabazitaxel and cisplatin before surgery to remove bladder cancer.

Cisplatin is a chemotherapy drug often used to treat bladder cancer which is usually given together with another drug such as gemcitabine. In this trial is testing the combination of cisplatin and a drug called cabazitaxel and how well this combination works for treating invasive transitional cell bladder cancer before surgery and more about the side effects.

CAB B1

Cancer type: Transitional cell cancer which has spread

This trial is looking at a chemotherapy drug called cabazitaxel.  It is for people who have transitional cell bladder cancer or cancer of urinary system that has spread into surrounding tissue or another part of the body despite chemotherapy.  The aim of the trial is to see if cabazitaxel helps people with transitional cell cancer that has spread and has got worse despite having platinum chemotherapy.

CALIBER

Cancer type: Low Risk non-invasive bladder cancer

Early stage bladder cancer is usually treated with surgery, which may be followed by intravesical treatment using a chemotherapy drug using mitomycin C.  Sometimes cancer can recur which may mean further surgery.  This trial is comparing mitomycin C with surgery as treatment for bladder cancer that has come back.  The aims of this trial are to find out if mitomycin C alone is an effective treatment to control cancer growth and more about any side effects and how treatment affects quality of life.

FIESTA

Cancer type: Locally advanced and/or metastatic

This is a Phase Ib trial (a very early phase of a clinical trial) of a new drug called AZD4547 in combination with gemcitabine and cisplatin.

HaBio

This study is using blood and urine samples to develop a test that will show why somebody has blood in their urine - haematuria.   Haematuria can be a symptom of bladder cancer, but there are other possible causes. 

The aim of the trial is to develop a simpler test for the causes of haematuria which may result in more efficient treatment as the cause is determined earlier, and may in the future lead to fewer people needing a cystoscopy.

This trial is recruiting people who have been diagnosed with bladder cancer and also people who have had negative results from tests for bladder cancer.

HYBRID

Cancer type: Muscle-invasive bladder cancer

NOTE: THIS TRIAL HAS NOW CLOSED FOR RECRUITMENT 

Invasive bladder cancer is usually treated with surgery or radiotherapy every day for several weeks.  Where surgery is not an option or a patient finds it difficult to cope with daily radiotherapy, people may be offered radiotherapy on a weekly basis for 6 weeks.

This trial is looking at how well this weekly radiotherapy works and at a new way of planning treatment called image guided adaptive planning and whether people who have adaptive radiotherapy have fewer side effects.

HIVEC II

Cancer type: non muscle-invasive bladder cancer

This trial is for people with newly diagnosed early bladder cancer or bladder cancer that has come back after initial treatment.

Hyperthermia is a new treatment where the bladder is heated to between 42° and 44° degrees centigrade and mitomycin C is washed through the bladder.

The trial is comparing hyperthermia and mitomycin C with mitomycin C alone. The aim of this trial is to find out which treatment is better at controlling cancer growth, more about the side effect and quality of life.

IDEAL

Cancer Type: Muscle-invasive bladder cancer

This trial is looking at combining 3 different ways to plan radiotherapy treatment for bladder cancer. This is so the doctors can target the cancer more accurately and give a higher dose of radiotherapy than they are normally able to.

MARBLE

This study is looking at some new scans to see if they can show how well treatment has worked in people having chemotherapy before surgery or radiotherapy for bladder cancer.

This trial is looking at new types of scans - a new MRI scan called fMRI (functional MRI scan) which may be better at showing how well treatment is working earlier on; and a new type of PET-CT scan called FLT PET-CT, which may be more effective at showing bladder cancer and giving more information.  You may not get any direct benefit from this trial yourself, but the results will be used to help others with bladder cancer in the future.

The study will recruit people having chemotherapy before radiotherapy or surgery for bladder cancer.

NEOBLADE

Cancer type: Muscle-invasive bladder cancer

This trial is looking at which combination of drugs works best for treating invasive bladder cancer.  The chemotherapy drugs gemcitabine and cisplatin will be used alongside a new drug called nintedanib for invasive bladder cancer.  Nintedanib (also known as BIBF 1120) is a type of biological therapy.

PHOTO

Cancer type: Non-invasive bladder cancer, newly diagnosed

This trial is no longer recruiting.

This trial is comparing a white light with a blue light during surgery (transurethral resection of bladder tumour or TURBT) for those recently diagnosed with early bladder cancer.

This trial looks at using a blue light during surgery which shows up a liquid which has been absorbed by the cancer cells and looks red under the blue light.  The aim is to compare this blue light with the standard white light to see which is most effective at showing cancer in the bladder.

POUT

This is a phase III multicentre randomised controlled trial to look at the effectiveness, safety and effects on quality of life of adjuvant chemotherapy in patients who have undergone radical nephro-ureterectomy for invasive cancer of the upper urinary tract.

TOTEM

Cancer type: Advanced bladder cancer which has spread into surrounding tissue or other parts of the body.

This trial is looking at how well a drug called temsirolimus (Torisel) works with cisplatin and gemcitabine chemotherapy in treating advanced transitional cell cancer, how safe this combination is, side effects and the best dose.  Temsirolimus is a type of biological therapy. It is a cancer growth blocker.

TUXEDO

Cancer type: Muscle-invasive bladder cancer

This trial is looking at a drug called cetuximab alongside radiotherapy and different types of chemotherapy for muscle-invasive bladder cancer.  Cetuximab is a biological therapy called a monoclonal antibody.  Those taking part may have already had some chemotherapy to shrink their cancer before radiotherapy.